Avanos Medical (NYSE: AVNS) completes acquisition of Nexus Medical

Rhea-AI Filing Summary

Avanos Medical, Inc. reported that on September 15, 2025 it acquired Nexus Medical, LLC. The company disclosed this event through a current report and referenced a press release that provides more information about the transaction.

The press release announcing the acquisition is attached as Exhibit 99.1 and is furnished under Regulation FD, meaning it is intended to share information broadly with the market but is not treated as filed for liability purposes under certain securities laws. Avanos’ common stock continues to trade on the New York Stock Exchange under the symbol AVNS.

Insights

Healthcare M&A analyst

Avanos adds Nexus Medical through an acquisition announced via Regulation FD.

Avanos Medical states that it has acquired Nexus Medical, LLC, signaling a strategic move to expand its business portfolio. The transaction is highlighted in a current report, with a dedicated press release attached as Exhibit 99.1 for additional context.

The disclosure is furnished under Regulation FD, which emphasizes broad, simultaneous communication to the market rather than detailed financial reporting in this document. The impact of the deal on revenue, earnings, and integration plans would depend on details contained in the Exhibit 99.1 press release and in future periodic reports that describe how Nexus Medical is incorporated into Avanos’ operations.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Avanos Medical (AVNS) announce in this 8-K filing?

Avanos Medical announced that it has acquired Nexus Medical, LLC and furnished a related press release as Exhibit 99.1.

When did Avanos Medical complete the acquisition of Nexus Medical, LLC?

Avanos Medical reported that it acquired Nexus Medical, LLC on September 15, 2025.

Where can investors find more details about Avanos Medical’s acquisition of Nexus Medical?

Additional information is provided in the press release attached as Exhibit 99.1, which is incorporated by reference in the current report.

How was the Nexus Medical acquisition information treated under securities regulations?

The acquisition and related press release are furnished under Item 7.01 Regulation FD Disclosure and are not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibit did Avanos Medical include with this 8-K related to the Nexus Medical deal?

Avanos Medical included Exhibit 99.1, a press release issued on September 15, 2025, along with an interactive data file identified as Exhibit 104.

On which exchange does Avanos Medical (AVNS) trade following the Nexus Medical acquisition?

Avanos Medical’s common stock with symbol AVNS continues to be listed on the New York Stock Exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/15/2025 - 07:05 AM Learn about SEC filing dates

0001606498falseSeptember 15, 202500016064982025-09-152025-09-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36440

46-4987888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

5405 Windward Parkway

Suite 100 South

Alpharetta,

Georgia

30004

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: (844) 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock - $0.01 Par Value			AVNS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01    Regulation FD Disclosure

On September 15, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing that the Company has acquired Nexus Medical, LLC. A copy of such press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein in its entirety.

The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d)Exhibits.

    The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.						Description
99.1						Press release issued by Avanos Medical, Inc. on September 15, 2025
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    

AVANOS MEDICAL, INC.

Date:

September 15, 2025

By:

/s/ Mojirade James

Mojirade James Senior Vice President and General Counsel